drugset / Trial / NCT00269828
A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2. Study drug will be administered on day 1 of each 21 day cycle
Timeline
- Start
- 2005-12
- Primary completion
- —
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | paclitaxel poliglumex | Other / unclassified | — | — |